We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Oxytocin and Emotion Recognition

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: October 7, 2010
Last Update Posted: October 7, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
University Hospital Freiburg
The present study was designed to investigate the effects of a single dose of synthetic oxytocin on facial emotion recognition in healthy adult man. Pictures of emotional faces are presented very briefly for a few milliseconds in a backward-masking paradigm in order to vary the level of awareness. In a randomized placebo-controlled between-subject design, recognition performance is compared between a drug (24 IU oxytocin) and a placebo condition. We hypothesize that oxytocin enhances emotion recognition even for facial stimuli processed with limited awareness.

Condition Intervention Phase
Health Drug: Syntocinon 24 IU Drug: Placebo Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science

Resource links provided by NLM:

Further study details as provided by University Hospital Freiburg:

Primary Outcome Measures:
  • Performance on a facial emotion recognition task [ Time Frame: 45 min. following drug administration ]

Enrollment: 56
Study Start Date: November 2009
Study Completion Date: January 2010
Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Oxytocin Drug: Syntocinon 24 IU
Placebo Comparator: Placebo Drug: Placebo


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Males
  • 18 to 40 years of age

Exclusion Criteria:

  • Any psychiatric diagnosis life-time
  • Somatic disease
  • IQ < 85
  • Smoker
  • Psychoactive medication
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01216605

Department of PSychiatry University of Rostock
Rostock, D, Germany, 18055
Sponsors and Collaborators
University Hospital Freiburg
Principal Investigator: Gregor Domes, PhD University of Freiburg
  More Information

ClinicalTrials.gov Identifier: NCT01216605     History of Changes
Other Study ID Numbers: X01A-DO1312/1-1
DO1312/1-1 ( Other Grant/Funding Number: German Research Foundation (DFG) )
First Submitted: October 6, 2010
First Posted: October 7, 2010
Last Update Posted: October 7, 2010
Last Verified: October 2010

Additional relevant MeSH terms:
Reproductive Control Agents
Physiological Effects of Drugs